Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 03:50PM GMT
Release Date Price: €75.76 (+1.69%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good morning, everyone, from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst, and it's my pleasure to introduce our next company, Sage Pharmaceuticals and CEO, Barry Greene. (Operator Instructions)

So with that, Barry, thanks for being here today, and let me hand things over to you.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Thanks, Cory, and thanks to the organizers of JPMorgan for having us here at the first ever virtual JPMorgan meeting. You guys have done a good job. It's certainly been very efficient.

Before I begin, I will be making forward-looking statements. So as Cory said, I'm Barry Greene, CEO of Sage Therapeutics, and it's my pleasure to provide an update on the extraordinary progress that Sage has made on brain health over the last decade, and importantly, provide my thoughts on what I believe our next chapter will be. At Sage, it's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot